Do we need to detect isoniazid resistance in addition to rifampicin resistance in diagnostic tests for tuberculosis?

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Denkinger, Claudia M ^a,b   Pai, Madhukar ^b,c   Dowdy, David W ^d,e  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b MCGILL UNIVERSITY   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID; RIFAMPICIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL TRANSMISSION; COMPARTMENT MODEL; EPIDEMIC; INCIDENCE; MORTALITY; MULTIDRUG RESISTANT TUBERCULOSIS; PREVALENCE; TUBERCULOSIS RAPID TEST;

ANTITUBERCULAR AGENTS; DIAGNOSTIC TESTS, ROUTINE; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; INCIDENCE; INDIA; ISONIAZID; MICROBIAL SENSITIVITY TESTS; MODELS, STATISTICAL; MORTALITY; MYCOBACTERIUM TUBERCULOSIS; PATIENT OUTCOME ASSESSMENT; POPULATION SURVEILLANCE; RIFAMPIN; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84896779657     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0084197     Document Type: Article

References (59)

1. World Health Organization (2012) Global tuberculosis report 2012. Geneva pp. 1-282.
2. World Health Organization (2011) Automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF system. Geneva
3. World Health Organization (2012) WHO monitoring of Xpert MTB/RIF rollout.
4. World Health Organization (2011) Rapid implementation of the Xpert MTB/RIF diagnostic test: technical and operational "How-to"; practical considerations. Geneva
5. Smith SE, Kurbatova EV, Cavanaugh JS, Cegielski JP (2012) Global isoniazid resistance patterns in rifampin-resistant and rifampin-susceptible tuberculosis. Int J Tuberc Lung Dis 16: 203-205.
6. Niemz A, Boyle DS (2012) Nucleic acid testing for tuberculosis at the point-ofcare in high-burden countries. Expert Rev Mol Diagn 12: 687-701.
7. Espinal MA, Kim SJ, Suarez PG, Kam KM, Khomenko AG, et al. (2000) Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries. JAMA 283: 2537-2545. (Pubitemid 30324196)
8. Mitnick C, Bayona J, Palacios E, Shin S, Furin J, et al. (2003) Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. N Engl J Med 348: 119-128. (Pubitemid 36056718)
9. Menzies NA, Cohen T, Lin HH, Murray M, Salomon JA (2012) Population health impact and cost-effectiveness of tuberculosis diagnosis with Xpert MTB/RIF: a dynamic simulation and economic evaluation. PLoS Med 9: e1001347.
10. Jenkins HE, Zignol M, Cohen T (2011) Quantifying the burden and trends of isoniazid resistant tuberculosis, 1994-2009. PLoS One 6: e22927.
11. Hong Kong Chest-British Medical Research Council (1981) Controlled trial of four twice-weekly regimens and a daily regimen all given for 6 months for pulmonary tuberculosis. Lancet: 171-174.
12. Menzies D, Benedetti A, Paydar A, Royce S, Madhukar P, et al. (2009) Standardized treatment of active tuberculosis in patients with previous treatment and/or with mono-resistance to isoniazid: a systematic review and meta-analysis. PLoS Med 6: e1000150.
13. Cattamanchi A, Dantes RB, Metcalfe JZ, Jarlsberg LG, Grinsdale J, et al. (2009) Clinical characteristics and treatment outcomes of patients with isoniazidmonoresistant tuberculosis. Clin Infect Dis 48: 179-185.
14. Jacobson KR, Theron D, Victor TC, Streicher EM, Warren RM, et al. (2011) Treatment outcomes of isoniazid-resistant tuberculosis patients, Western Cape Province, South Africa. Clin Infect Dis 53: 369-372.
15. Mitchison DA, Nunn AJ (1986) Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis. Am Rev Respir Dis 133: 423-430. (Pubitemid 16126276)
16. World Health Organization (2008) Molecular line probe assays for rapid screening of patients at risk for multidrug-resistant tuberculosis (MDR-TB).
17. World Health Organization (2012) Global Tuberculosis Control: WHO report 2012. Geneva: WHO. 1-272 p.
18. Anderson RM, May RM (1991) Infectious diseases of humans: dynamics and control. Oxford: Oxford University Press.
19. Dye C, Garnett GP, Sleeman K, Williams BG (1998) Prospects for worldwide tuberculosis control under the WHO DOTS strategy. Directly observed shortcourse therapy. Lancet 352: 1886-1891. (Pubitemid 28561249)
20. Revised National Tuberculosis Control Program I (2011) Performance data on Tuberculosis Control.
21. Cohn DL, Bustreo F, Raviglione MC (1997) Drug-resistant tuberculosis: review of the worldwide situation and the WHO/IUATLD Global Surveillance Project. International Union Against Tuberculosis and Lung Disease. Clin Infect Dis 24 Suppl 1: S121-130.
22. Paramasivan CN, Chandrasekaran V, Santha T, Sudarsanam NM, Prabhakar R (1993) Bacteriological investigations for short-course chemotherapy under the tuberculosis programme in two districts of India. Tuber Lung Dis 74: 23-27. (Pubitemid 23080931)
23. Girosi F, Olmsted SS, Keeler E, Hay Burgess DC, Lim YW, et al. (2006) Developing and interpreting models to improve diagnostics in developing countries. Nature 444 Suppl 1: 3-8.
24. Nikam C, Jagannath M, Narayanan MM, Ramanabhiraman V, Kazi M, et al. (2013) Rapid Diagnosis of Mycobacterium tuberculosis with Truenat MTB: A Near-Care Approach. PLoS One 8: e51121.
25. Steingart KR, Sohn H, Schiller I, Kloda LA, Boehme CC, et al. (2013) Xpert(R) MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst Rev 1: CD009593.
26. Ling DI, Zwerling AA, Pai M (2008) Geno Type MTBDR assays for the diagnosis of multidrug-resistant tuberculosis: a meta-analysis. Eur Respir J 32: 1165-1174.
27. Dorman SE, Johnson JL, Goldberg S, Muzanye G, Padayatchi N, et al. (2009) Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. Am J Respir Crit Care Med 180: 273-280.
28. Law S, Benedetti A, Oxlade O, Schwartzman K, Menzies D (2013) Comparing cost-effectiveness of standardized TB treatments given varying drug-resistance. Eur Respir J.
29. Bhargava A, Pinto L, Pai M (2011) Mismanagement of tuberculosis in India: Causes, consequences, and the way forward. Hypothesis 9: e7.
30. Cohen T, Murray M (2004) Modeling epidemics of multidrug-resistant M. tuberculosis of heterogeneous fitness. Nat Med 10: 1117-1121. (Pubitemid 39424874)
31. Vandan N, Ali M, Prasad R, Kuroiwa C (2009) Assessment of doctors' knowledge regarding tuberculosis management in Lucknow, India: a publicprivate sector comparison. Public Health 123: 484-489.
32. World Health Organization (2008) Anti-Tuberculosis Drug Resistance in the World. The WHO/UNION Global Project on Anti-Tuberculosis Drug Resistance Surveillance.
33. Andrews JR, Shah NS, Gandhi N, Moll T, Friedland G (2007) Multidrugresistant and extensively drug-resistant tuberculosis: implications for the HIV epidemic and antiretroviral therapy rollout in South Africa. J Infect Dis 196 Suppl 3: S482-490. (Pubitemid 351417242)
34. Coninx R, Mathieu C, Debacker M, Mirzoev F, Ismaelov A, et al. (1999) Firstline tuberculosis therapy and drug-resistant Mycobacterium tuberculosis in prisons. Lancet 353: 969-973. (Pubitemid 29132606)
35. Wells CD, Cegielski JP, Nelson LJ, Laserson KF, Holtz TH, et al. (2007) HIV infection and multidrug-resistant tuberculosis: the perfect storm. J Infect Dis 196 Suppl 1: S86-107.
36. Balcells ME, Thomas SL, Godfrey-Faussett P, Grant AD (2006) Isoniazid preventive therapy and risk for resistant tuberculosis. Emerg Infect Dis 12: 744-751. (Pubitemid 43726847)
37. Cohen T, Lipsitch M, Walensky RP, Murray M (2006) Beneficial and perverse effects of isoniazid preventive therapy for latent tuberculosis infection in HIV tuberculosis coinfected populations. Proc Natl Acad Sci U S A 103: 7042-7047.
38. World Health Organization (2011) Global tuberculosis report 2011. Geneva pp. 1-246.
39. Styblo K (1991) Epidemiology of tuberculosis. The Hague, The Netherlands: Royal Netherlands Tuberculosis Association (KNCV).
40. Pym AS, Saint-Joanis B, Cole ST (2002) Effect of katG mutations on the virulence of Mycobacterium tuberculosis and the implication for transmission in humans. Infect Immun 70: 4955-4960.
41. van Soolingen D, de Haas PE, van Doorn HR, Kuijper E, Rinder H, et al. (2000) Mutations at amino acid position 315 of the katG gene are associated with high-level resistance to isoniazid, other drug resistance, and successful transmission of Mycobacterium tuberculosis in the Netherlands. J Infect Dis 182: 1788-1790.
42. Billington OJ, McHugh TD, Gillespie SH (1999) Physiological cost of rifampin resistance induced in vitro in Mycobacterium tuberculosis. Antimicrob Agents Chemother 43: 1866-1869. (Pubitemid 29395177)
43. Gagneux S, Long CD, Small PM, Van T, Schoolnik GK, et al. (2006) The competitive cost of antibiotic resistance in Mycobacterium tuberculosis. Science 312: 1944-1946. (Pubitemid 43993719)
44. Sutherland I, Svandova E, Radhakrishna S (1982) The development of clinical tuberculosis following infection with tubercle bacilli. 1. A theoretical model for the development of clinical tuberculosis following infection, linking from data on the risk of tuberculous infection and the incidence of clinical tuberculosis in the Netherlands. Tubercle 63: 255-268.
45. Andrews JR, Noubary F, Walensky RP, Cerda R, Losina E, et al. (2012) Risk of progression to active tuberculosis following reinfection with Mycobacterium tuberculosis. Clin Infect Dis 54: 784-791.
46. van Leth F, van der Werf MJ, Borgdorff MW (2008) Prevalence of tuberculous infection and incidence of tuberculosis: a re-assessment of the Styblo rule. Bull World Health Organ 86: 20-26.
47. Vynnycky E, Fine PE (1997) The natural history of tuberculosis: the implications of age-dependent risks of disease and the role of reinfection. Epidemiol Infect 119: 183-201. (Pubitemid 27474799)
48. Ferebee SH (1970) Controlled chemoprophylaxis trials in tuberculosis. A general review. Bibl Tuberc 26: 28-106.
49. Grzybowski S, Enarson D (1978) [Results in pulmonary tuberculosis patients under various treatment program conditions]. Bull Int Union Tuberc 53: 70-75. (Pubitemid 9240283)
50. Etard JF, Ndiaye I, Thierry-Mieg M, Gueye NF, Gueye PM, et al. (2006) Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: a 7-year cohort study. AIDS 20: 1181-1189. (Pubitemid 43786107)
51. Boehme CC, Nicol MP, Nabeta P, Michael JS, Gotuzzo E, et al. (2011) Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. Lancet 377: 1495-1505.
52. Chang K, Lu W, Wang J, Zhang K, Jia S, et al. (2012) Rapid and effective diagnosis of tuberculosis and rifampicin resistance with Xpert MTB/RIF assay: A meta-analysis. J Infect 64: 580-588.
53. Botha E, Den Boon S, Verver S, Dunbar R, Lawrence KA, et al. (2008) Initial default from tuberculosis treatment: how often does it happen and what are the reasons? Int J Tuberc Lung Dis 12: 820-823. (Pubitemid 351976715)
54. Khan MS, Khan S, Godfrey-Faussett P (2009) Default during TB diagnosis: quantifying the problem. Trop Med Int Health 14: 1437-1441.
55. [No author listed] (1984) A controlled trial of 6 months' chemotherapy in pulmonary tuberculosis. Final report: results during the 36 months after the end of chemotherapy and beyond. British Thoracic Society. Br J Dis Chest 78: 330-336.
56. Lew W, Pai M, Oxlade O, Martin D, Menzies D (2008) Initial drug resistance and tuberculosis treatment outcomes: systematic review and meta-analysis. Ann Intern Med 149: 123-134. (Pubitemid 352008599)
57. Menzies D, Benedetti A, Paydar A, Martin I, Royce S, et al. (2009) Effect of duration and intermittency of rifampin on tuberculosis treatment outcomes: a systematic review and meta-analysis. PLoS Med 6: e1000146.
58. Seung KJ, Gelmanova IE, Peremitin GG, Golubchikova VT, Pavlova VE, et al. (2004) The effect of initial drug resistance on treatment response and acquired drug resistance during standardized short-course chemotherapy for tuberculosis. Clin Infect Dis 39: 1321-1328. (Pubitemid 39458518)
59. Centers for Disease C, Prevention (1999) Primary multidrug-resistant tuberculosis-Ivanovo Oblast, Russia, 1999. MMWR Morb Mortal Wkly Rep 48: 661-664.